Copd Newswire (Page 8)

Copd Newswire (Page 8)

Comprehensive Real-Time News Feed for Copd. (Page 8)

Results 141 - 160 of 409 in Copd

  1. ProterixBio Joins The Industrial Advisory Boards Of The And TheRead the original story

    Sep 12, 2016 | BioSpace

    Joining both advisory boards reflects ProterixBio's commitment to develop novel clinical applications including diagnostics products and disease management tools for pulmonary diseases. ProterixBio is developing innovative products to transform the management of chronic diseases, with the initial applications focusing on pulmonary diseases such as COPD, cystic fibrosis and idiopathic pulmonary fibrosis .

    Comment?

  2. Consort Medical Release: New Scale-Up And Commercial Supply AgreementRead the original story

    Sep 11, 2016 | BioSpace

    ... for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. AstraZeneca announced that its device was approved by the US Food and Drug ...

    Comment?

  3. Non-Drug Device Reduces COPD ExacerbationsRead the original story w/Photo

    Sep 10, 2016 | PR Log

    ... a real-world study, evaluating the efficacy of the AerobikaA device in reducing chronic obstructive pulmonary disease (COPD) exacerbations. PLATTSBURGH, N.Y. - Sept. 11, 2016 - PRLog -- Monaghan Medical Corporation (MMC) today announced results from ...

    Comment?

  4. COPD Exacerbations Lead to Lung Function Decline, Particularly Among Those with Mild COPDRead the original story

    Sep 8, 2016 | Newswise

    Newswise - Sept. 8, 2016 a' Acute exacerbations of chronic obstructive pulmonary disease, or COPD, are associated with significant long-term lung function loss, according to research published online, ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

    Comment?

  5. Theravance Biopharma Highlights Positive Results From Pivotal Phase 3 ...Read the original story

    Sep 7, 2016 | BioSpace

    ... furoate, umeclidinium, and vilanterol or FF/UMEC/VI) in patients with chronic obstructive pulmonary disease (COPD). Data presented at the European Respiratory Society (ERS) International Congress demonstrated clinically meaningful and statistically ...

    Comment?

  6. Analyzing The AnalystsRead the original story w/Photo

    Sep 8, 2016 | Seeking Alpha

    ... products, among which one of the probably most important pipeline assets in GSK's portfolio, the "closed triple." COPD (Chronic Obstructive Pulmonary Disease) affects about 64 million people worldwide. In the U.S. alone, there are probably about 24 ...

    Comment?

  7. Theravance Biopharma Touts Significant Data from Pivotal Phase III Fulfil StudyRead the original story

    Sep 7, 2016 | BioSpace

    ... furoate, umeclidinium, and vilanterol or FF/UMEC/VI) in patients with chronic obstructive pulmonary disease (COPD). Data presented at the European Respiratory Society (ERS) International Congress demonstrated clinically meaningful and statistically ...

    Comment?

  8. GlaxoSmithKline: A Dream FULFILledRead the original story w/Photo

    Sep 7, 2016 | Seeking Alpha

    ... marketing battle. In fact, when the study was designed, GSK and AZN were on schedule to launch triple combinations for COPD at about the same time in the U.S. - and AZN's triple is based exactly on Symbicort to which it adds a LAMA. So, if GSK could ...

    Comment?

  9. Lyn ClevengerRead the original story w/Photo

    Sep 6, 2016 | The Hutchinson News, Hutchinson Kansas

    ... Service will be held at 11 a.m. Saturday at the Bucklin Cemetery with Reverend Dick Robbins officiating. Memorials: COPD Foundation, care of Minnis Mortuary, Box 516, Bucklin, KS 67834. CANON CITY, Colo. - Lyn Clevenger died Aug. 29, 2016. He is ...

    Comment?

  10. GSK presents positive results from phase III Fulfil study of closed...Read the original story

    Sep 6, 2016 | PressReleasePoint

    GlaxoSmithKline plc and Innoviva, Inc. today announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease , at the European Respiratory Society International Congress taking place in London this week. The FULFIL study was designed to evaluate the effects of once daily FF/UMEC/VI compared with twice daily SymbicortA TurbohalerA in patients with advanced COPD.

    Comment?

  11. GlaxoSmithKline Presents Positive Results From Phase III Fulfil Study ...Read the original story

    Sep 5, 2016 | BioSpace

    GlaxoSmithKline Presents Positive Results From Phase III Fulfil Study Of Closed Triple Combination Therapy Ff/Umec/Vi Versus Symbicort Turbohaler In COPD At ERS International Congress LONDON & BRISBANE, Calif.-- --GlaxoSmithKline plc and Innoviva, Inc. today announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease , at the European Respiratory Society International Congress taking place in London this week.

    Comment?

  12. GlaxoSmithKline And Innoviva Release: Positive Results From The COPD...Read the original story

    Sep 5, 2016 | BioSpace

    ... to evaluate the effectiveness and safety of RelvarA ElliptaA in patients with chronic obstructive pulmonary disease (COPD), compared with their 'usual care' administered in an everyday clinical practice setting. Data from the study are being ...

    Comment?

  13. Boehringer Ingelheim Release: Simple Blood Test Combined With...Read the original story

    Sep 5, 2016 | BioSpace

    ... Congress 2016 in "New results from the WISDOM study indicate that using ICS as part of a triple therapy regimen in COPD maintenance treatment reduces the likelihood of an exacerbation for a smaller number of people than previously thought. It ...

    Comment?

  14. Respiratory Monitoring Devices Market - Analysis, Size, Share,...Read the original story w/Photo

    Sep 5, 2016 | PR Newswire

    ... period from 2015 to 2023 , considering 2014 as the base year. A brief annual cost estimation, prevalence of asthma and COPD, average pricing analysis, reimbursement scenario have also been discussed in the global respiratory monitoring devices ...

    Comment?

  15. Simple Blood Test Combined with Exacerbation History May Help to Identify When to...Read the original story w/Photo

    Sep 5, 2016 | Freshnews

    ... 2016 in London. "New results from the WISDOM study indicate that using ICS as part of a triple therapy regimen in COPD maintenance treatment reduces the likelihood of an exacerbation for a smaller number of people than previously thought. It ...

    Comment?

  16. BRIEF-GlaxoSmithKline sees positive results from COPD Salford Lung studyRead the original story w/Photo

    Sep 5, 2016 | Reuters

    * Results from sls provide robust evidence that will enable healthcare community to begin to understand how choice of copd treatment can significantly influence patient outcomes. Source text for Eikon: Further company coverage: (Reporting By UK ...

    Comment?

  17. GlaxoSmithKline's Relvar Ellipta shows 'significant' test score for COPDRead the original story w/Photo

    May 9, 2016 | Live Charts

    ... found a statistically significant reduction in the rate of attacks suffered by chronic obstructive pulmonary disease (COPD) patients compared to when they receive the standard treatment. The pioneering Salford Lung Study by GSK and its partner on ...

    Comment?

  18. Positive Results From the COPD Salford L ...Read the original story

    Sep 4, 2016 | The Financial Mirror

    ... to evaluate the effectiveness and safety of RelvarA ElliptaA in patients with chronic obstructive pulmonary disease (COPD), compared with their 'usual care' administered in an everyday clinical practice setting. Data from the study are being ...

    Comment?

  19. AstraZeneca, Glaxo Explore Prevention Potential of Asthma ShotsRead the original story

    Sep 3, 2016 | The Washington Post

    ... people suffer from asthma and the lung conditions known collectively as chronic obstructive pulmonary disease, or COPD, according to AstraZeneca. "The dream for the long-term is that you intervene in asthma earlier with a medicine that could ...

    Comment?

  20. Boehringer Ingelheim Pharmaceuticals Inc.Read the original story

    Aug 31, 2016 | PressReleasePoint

    The collaboration will be announced at Qualcomm Life's fifth annual Connect 2016 ecosystem conference, taking place on August 30 and August 31, 2016 in San Diego, California. For more than 40 years, Boehringer Ingelheim has had an unwavering commitment to the COPD community to provide new health solutions that can help improve patient outcomes and expand our understanding of COPD, " said Ruchin Kansal, Executive Director and Head, Business Innovation, Boehringer Ingelheim Pharmaceuticals, Inc. "Boehringer Ingelheim is proud to join forces with Qualcomm Life, a global leader in wireless technologies, to bring the latest technology to our RESPIMAT inhaler with the goal of improving adherence to daily medicines that treat symptoms of COPD."

    Comment?